Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The AML Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Latest Videos The AML Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Acute Myeloid Leukemia (AML) Channel

VJHemOnc brings you the latest and greatest global advances related to the classification, diagnosis, treatment, and management of AML. Speaking with world-leading experts, The AML Channel delivers video interviews, podcasts, roundtable discussions, and more.

Hot topics frequently covered on The AML Channel include the use of measurable residual disease (MRD) testing to guide treatment, targeted agents, and CAR T-cell therapies.

Conferences

iwAL 2025
SOHO 2025
EHA 2025
ASCO 2025
EBMT 2025
ISAL 2025
14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddocket al. • 21 Oct 2025
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
2:13
One big question with Gail Roboz: what AML advance could transform frontline care in three years?
Gail Roboz • 26 Sep 2025
3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
View All Videos
1:47
Advances in MRD-guided therapy in AML & strategies being explored to eradicate MRD
Eytan Stein • 5 Sep 2025
2:06
The future of menin inhibition in AML: combination strategies
Eytan Stein • 5 Sep 2025
3:52
ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
Abhishek Maiti • 9 Sep 2025
1:54
The value of lower-intensity regimens in AML treatment
Jennifer Marvin-Peek • 5 Sep 2025
View All Videos
6:43
The Phase III QuANTUM-Wild trial: quizartinib in newly diagnosed FLT3-ITD-negative AML
Harry Erba • 12 Jun 2025
1:41
Combining targeted agents with existing backbones to improve outcomes in AML
Gail Roboz • 14 Jun 2025
2:00
Prolonging remission in AML: stem cell transplantation or continuous treatment
Gail Roboz • 14 Jun 2025
1:51
What is the role of MRD monitoring for FLT3mut+ AML?
Mark Levis • 13 Jun 2025
View All Videos
1:26
The use of olutasidenib in R/R AML: an analysis of outcomes by number of prior treatment regimens
Eunice Wang • 2 Jun 2025
1:28
Update on the KOMET-001 trial: ziftomenib in NPM1-mutant AML
Eunice Wang • 2 Jun 2025
3:56
Key factors that influence conditioning intensity and moving toward personalized conditioning in AML
Uday Popat • 28 May 2025
7:35
A myeloablative fractionated busulfan conditioning regimen with sorafenib for alloSCT in AML
Uday Popat • 28 May 2025
View All Videos
2:06
The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
Evelyn Ullrich • 11 Apr 2025
0:53
Impact of melphalan dose combined with fludarabine on GI toxicity & GvHD after alloSCT in AML/MDS
Nelli Bejanyan • 1 Apr 2025
3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
5:36
The role of NGS profiling in patients with AML undergoing alloSCT
Ali Bazarbachi • 10 Apr 2025
View All Videos
7:31
Menin inhibition in AML: clinical guidance and future directions
Charles Craddocket al. • 18 Mar 2025
10:35
Venetoclax resistance in AML
Curtis Lachowiezet al. • 17 Mar 2025
0:58
Findings from a Phase III trial of azacitidine and venetoclax plus pevonedistat in AML
Cristina Papayannidis • 17 Mar 2025
2:49
Implementing computational MRD assessment into clinical practice: challenges and solutions
Costa Bachas • 19 Mar 2025
View All Videos

Topics

MRD
Transplant
CAR-T & Cellular Therapy
Real-World Data
Trial Updates
Immuno-Oncology
14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddocket al. • 21 Oct 2025
2:13
One big question with Gail Roboz: what AML advance could transform frontline care in three years?
Gail Roboz • 26 Sep 2025
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
1:47
Advances in MRD-guided therapy in AML & strategies being explored to eradicate MRD
Eytan Stein • 5 Sep 2025
View All Videos
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
1:47
Advances in MRD-guided therapy in AML & strategies being explored to eradicate MRD
Eytan Stein • 5 Sep 2025
1:46
Optimizing therapy and extending survival in AML: balancing efficacy and toxicity
Alexander Perl • 5 Sep 2025
View All Videos
16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
Andrew Weiet al. • 19 Sep 2025
1:25
Perspectives on the promise and challenges of NK cell therapies in AML
John DiPersio • 19 Sep 2025
17:15
Immunotherapy in AML: translational insights and promising avenues being explored
Ann-Kathrin Eisfeldet al. • 20 Sep 2025
1:51
Immune-based strategies in AML: current limitations and novel targets being explored
David Sallman • 4 Sep 2025
View All Videos
2:17
Real-world safety & outcomes with gemtuzumab ozogamicin and 7+3 in patients with newly diagnosed AML
Elizabeth Herrity • 13 Jun 2025
5:36
The role of NGS profiling in patients with AML undergoing alloSCT
Ali Bazarbachi • 10 Apr 2025
2:23
Allogeneic transplantation in elderly patients: insights from Brazilian registry data
Fernando Barroso Duarte • 30 Mar 2025
4:20
Outcomes of patients with AML in adverse cytogenetic subgroups undergoing alloSCT in first remission
Ali Bazarbachi • 10 Apr 2025
View All Videos
3:52
ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
Abhishek Maiti • 9 Sep 2025
1:49
Efficacy and safety of olutasidenib monotherapy in relapsed/refractory AML
Jorge Cortes • 4 Sep 2025
2:19
Updated results from the AUGMENT-101 study: revumenib in R/R KMT2A-rearranged or NPM1-mutated AML
Eytan Stein • 5 Sep 2025
2:08
Could MRD become a surrogate endpoint for drug approval in AML?
Alexander Perl • 3 Sep 2025
View All Videos
14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddocket al. • 21 Oct 2025
3:52
ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
Abhishek Maiti • 9 Sep 2025
6:45
γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML
Abhishek Maiti • 10 Sep 2025
11:48
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Naval Daver • 21 Sep 2025
View All Videos

david-sallman
David Sallman
MD
H. Lee Moffitt Cancer Center & Research Institute
paresh-vyas
Paresh Vyas
MRCP, FRCP, FRCPath
Weatherall Institute of Molecular Medicine, University of Oxford
thomas-cluzeau
Thomas Cluzeau
MD, PhD
Central University Hospital of Nice
eunice-wang
Eunice Wang
MD
Roswell Park Comprehensive Cancer Center
eytan-stein
Eytan Stein
MD
Memorial Sloan Kettering Cancer Center

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Silver Supporter

BMS

If you are interested in becoming a supporter of The Acute Myeloid Leukemia Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals